Free tool
FAERS Monitor: Suprane
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020118 or its brand name (Suprane, Desflurane). Reports on generic versions are filed under their own applications.
Reports
1,717
Serious
1,636
95% of reports
Hospitalization
664
Death reported
112
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hypotension119
- bradycardia103
- cardiac arrest99
- drug interaction97
- anaphylactic shock93
- serotonin syndrome74
- hyperthermia malignant64
- anaphylactic reaction59
- bronchospasm58
- drug ineffective58
- tachycardia57
- foetal exposure during pregnancy48
- post procedural complication42
- blood pressure decreased41
- circulatory collapse37
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 20 |
| 2005 | 37 |
| 2006 | 36 |
| 2007 | 30 |
| 2008 | 57 |
| 2009 | 55 |
| 2010 | 68 |
| 2011 | 66 |
| 2012 | 95 |
| 2013 | 118 |
| 2014 | 105 |
| 2015 | 120 |
| 2016 | 108 |
| 2017 | 116 |
| 2018 | 138 |
| 2019 | 114 |
| 2020 | 84 |
| 2021 | 76 |
| 2022 | 61 |
| 2023 | 65 |
| 2024 | 64 |
| 2025 | 46 |
| 2026 | 37 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,442 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyperthermia malignantSignal | 64 | 550.7 | 430.6 | 33,084 |
| bronchospasmSignal | 58 | 50.0 | 38.8 | 2,726 |
| serotonin syndromeSignal | 74 | 47.4 | 37.9 | 3,303 |
| anaphylactic shockSignal | 93 | 44.4 | 36.4 | 3,889 |
| post procedural complicationSignal | 42 | 26.8 | 19.9 | 1,018 |
| circulatory collapseSignal | 37 | 26.7 | 19.4 | 887 |
| bradycardiaSignal | 103 | 23.8 | 19.8 | 2,232 |
| cardiac arrestSignal | 99 | 14.7 | 12.1 | 1,254 |
| anaphylactic reactionSignal | 59 | 13.1 | 10.2 | 648 |
| tachycardiaSignal | 57 | 7.9 | 6.1 | 336 |
| blood pressure decreasedSignal | 41 | 7.6 | 5.6 | 228 |
| drug interactionSignal | 97 | 7.5 | 6.2 | 543 |
| hypotensionSignal | 119 | 7.3 | 6.1 | 643 |
| foetal exposure during pregnancySignal | 48 | 7.2 | 5.5 | 253 |
| drug ineffective | 58 | 0.5 | 0.4 | 24 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.